• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Mirum Pharmaceuticals (MIRM) Phase 3 Win Sets Up FDA Plans, Is It Still 38% Below Fair Value?

    Simply Wall St·11/11/2026 20:24:36
    Listen to the news

    Mirum Pharmaceuticals (MIRM) just reported that its Phase 3 AZURE-4 trial of brelovitug for chronic hepatitis delta virus met its primary endpoint, with both efficacy and safety outcomes supporting a planned U.S. FDA filing.

    Mirum Pharmaceuticals has seen its recent clinical headlines arrive alongside solid price momentum, with the share price up 8.49% over the past week and 9.78% over the last month, although the 90 day share price return is down 4.60%.

    Capitalize on Mirum Pharmaceuticals’ rare disease momentum and use it as a blueprint to scout other niche healthcare opportunities across our hand picked 36 healthcare AI stocks.

    Mirum Pharmaceuticals just added a fresh clinical win on top of an already strong multi year share price run. The key tension now is whether recent gains captured most of the upside or if valuation still leaves meaningful room ahead.

    Most Popular Narrative: 38% Undervalued

    Mirum Pharmaceuticals closed at $94.42 compared with the analyst consensus Narrative fair value of $153.43. This suggests a wide implied discount using a 7.68% discount rate in the analyst consensus Narrative on Simply Wall St.

    The expanding addressable patient population for Mirum Pharmaceuticals therapies, especially with the increased recognition and diagnosis of later onset PFIC through broader use of genetic testing and heightened disease awareness, is associated with higher than expected patient volumes that can support sustained revenue generation.

    Continued advances in precision medicine and genetics, including Mirum sponsored exome testing programs for unexplained cholestasis, early onset cataracts and PBD ZSD, are improving rare disease diagnosis rates and can accelerate patient identification for Mirum Pharmaceuticals products, which may support revenue and earnings through earlier and broader therapy adoption.

    See why 12 investors see Mirum Pharmaceuticals as 38% undervalued.

    Result: Fair Value of $153.43 (UNDERVALUED)

    Still, Mirum Pharmaceuticals leans heavily on LIVMARLI today, and any delay or setback across Brelovitug, Atebrioz or volixibat could quickly challenge this bullish narrative.

    Find out about the key risks to this Mirum Pharmaceuticals narrative.

    Next Steps

    Sentiment on Mirum Pharmaceuticals is clearly split, with clinical progress on one side and meaningful watchpoints on the other. Move quickly, review the data for yourself, and weigh both the upside and the concerns across the 4 key rewards and 2 important warning signs.

    Looking for more Mirum Pharmaceuticals sized ideas?

    Do not stop with Mirum Pharmaceuticals. Use this momentum to refresh your watchlist and line up the next set of targets before the market moves first.